Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony D Ho

Showing results (251-260 of 346) with videos related to

Pageof 35
Sort By:
European Journal of Haematology|September 7, 2004
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphomaEugen Leo, Lars Scheuer, Ingo G H Schmidt-Wolf, et al.
Cancer|March 7, 2007
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisisStefan Fruehauf, Julian Topaly, Eike C Buss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2011
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cellsSascha Dietrich, Oliver H Krämer, Esther Hahn, et al.
Transplantation|October 24, 2014
Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantationSascha Dietrich, Aleksandar Radujkovic, Friedrich Stölzel, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
International Journal of Cancer|May 13, 2016
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapyAleksandar Radujkovic, Sascha Dietrich, Mindaugas Andrulis, et al.
European Journal of Haematology|October 18, 2006
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationJens Klaus, Doris Herrmann, Iris Breitkreutz, et al.
Cancer Discovery|April 25, 2013
Targeting the BRAF V600E mutation in multiple myelomaMindaugas Andrulis, Nicola Lehners, David Capper, et al.
Pageof 35

Showing results (251-260 of 346) with videos related to

Sort By:
Pageof 35
European Journal of Haematology|September 7, 2004
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphomaEugen Leo, Lars Scheuer, Ingo G H Schmidt-Wolf, et al.
Cancer|March 7, 2007
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisisStefan Fruehauf, Julian Topaly, Eike C Buss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2011
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cellsSascha Dietrich, Oliver H Krämer, Esther Hahn, et al.
Transplantation|October 24, 2014
Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantationSascha Dietrich, Aleksandar Radujkovic, Friedrich Stölzel, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
International Journal of Cancer|May 13, 2016
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapyAleksandar Radujkovic, Sascha Dietrich, Mindaugas Andrulis, et al.
European Journal of Haematology|October 18, 2006
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationJens Klaus, Doris Herrmann, Iris Breitkreutz, et al.
Cancer Discovery|April 25, 2013
Targeting the BRAF V600E mutation in multiple myelomaMindaugas Andrulis, Nicola Lehners, David Capper, et al.
Pageof 35